Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
Immunoteràpia del càncer; Resistència terapèutica del càncer
| Authors: | ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2021 |
| Country: | España |
| Institution: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repository: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:11351/6893 |
| Online Access: | https://hdl.handle.net/11351/6893 |
| Access Level: | Open access |
| Keyword: | Càncer - Immunoteràpia Resistència als medicaments DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/immunology PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/inmunología FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos |
| _version_ | 1878742023163346944 |
|---|---|
| author | Román Alonso, Macarena |
| author2 | Luque García, Antonio Fajardo, Carlos Alberto Gros Vidal, Alena Arribas López, Joaquin Vicente Arenas Lahuerta, Enrique Javier Martínez-Sabadell, Alex Rius Ruiz, Irene Escorihuela Baez, Marta |
| author2_role | author author author author author author author author |
| author_browse | Arenas Lahuerta, Enrique Javier Arribas López, Joaquin Vicente Escorihuela Baez, Marta Fajardo, Carlos Alberto Gros Vidal, Alena Luque García, Antonio Martínez-Sabadell, Alex Rius Ruiz, Irene Román Alonso, Macarena |
| author_facet | Román Alonso, Macarena Luque García, Antonio Fajardo, Carlos Alberto Gros Vidal, Alena Arribas López, Joaquin Vicente Arenas Lahuerta, Enrique Javier Martínez-Sabadell, Alex Rius Ruiz, Irene Escorihuela Baez, Marta |
| author_role | author |
| collection | Recercat. Dipósit de la Recerca de Catalunya |
| description | Immunoteràpia del càncer; Resistència terapèutica del càncer |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_eeefcd63e2d4abafb186ffe6b5de35a5 |
| institution | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:recercat.cat:11351/6893 |
| publishDate | 2021 |
| publishDateSort | 2021 |
| publisher | Nature Research |
| publisherStr | Nature Research |
| reponame_str | Recercat. Dipósit de la Recerca de Catalunya |
| spelling | Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation Román Alonso, Macarena Luque García, Antonio Fajardo, Carlos Alberto Gros Vidal, Alena Arribas López, Joaquin Vicente Arenas Lahuerta, Enrique Javier Martínez-Sabadell, Alex Rius Ruiz, Irene Escorihuela Baez, Marta Càncer - Immunoteràpia Resistència als medicaments DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/immunology PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/inmunología FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos Immunoteràpia del càncer; Resistència terapèutica del càncer Inmunoterapia contra el cáncer; Resistencia terapéutica del cáncer Cancer immunotherapy; Cancer therapeutic resistance Immunotherapy has raised high expectations in the treatment of virtually every cancer. Many current efforts are focused on ensuring the efficient delivery of active cytotoxic cells to tumors. It is assumed that, once these active cytotoxic cells are correctly engaged to cancer cells, they will unfailingly eliminate the latter, provided that inhibitory factors are in check. T cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs) offer an opportunity to test this assumption. Using TCB and CARs directed against HER2, here we show that disruption of interferon-gamma signaling confers resistance to killing by active T lymphocytes. The kinase JAK2, which transduces the signal initiated by interferon-gamma, is a component repeatedly disrupted in several independently generated resistant models. Our results unveil a seemingly widespread strategy used by cancer cells to resist clearance by redirected lymphocytes. In addition, they open the possibility that long-term inhibition of interferon-gamma signaling may impair the elimination phase of immunoediting and, thus, promote tumor progression. Nature Research https://hdl.handle.net/11351/6893 |
| spellingShingle | Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation Román Alonso, Macarena Càncer - Immunoteràpia Resistència als medicaments DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/immunology PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/inmunología FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos |
| status_str | publishedVersion |
| title | Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation |
| title_full | Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation |
| title_fullStr | Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation |
| title_full_unstemmed | Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation |
| title_short | Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation |
| title_sort | Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation |
| topic | Càncer - Immunoteràpia Resistència als medicaments DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/immunology PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/inmunología FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos |
| topic_facet | Càncer - Immunoteràpia Resistència als medicaments DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/immunology PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/inmunología FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos |
| url | https://hdl.handle.net/11351/6893 |